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Cardiac complications after hematopoietic stem cell transplantation (HSCT) can lead to signiﬁcant morbidity
and mortality. Cardiac evaluation during the ﬁrst 100 days after HSCT is usually performed only if clinically
indicated, and no studies have examined whether routine screening is beneﬁcial in this patient population
at high risk for tissue injury. We conducted a single-center prospective clinical study to screen for cardiac
complications in pediatric and young adult patients. One hundred consecutive HSCT patients underwent
scheduled echocardiographic screening on dayþ7 after transplantation, independent of their clinical condition.
At least 1 abnormality was identiﬁed in 30% of cases. Seventeen children had a pericardial effusion, 13 elevated
right ventricular pressure, and 3 reduced left ventricular function. Survival was reduced in children with any
echocardiographic abnormality at day 7 (67% versus 80% in those with and without, respectively, abnormality,
P ¼ .073). Moreover, raised right ventricular pressure at day þ7 was signiﬁcantly associated with transplant-
associated thrombotic microangiopathy (TA-TMA; P ¼ .004) and may indicate early vascular injury in the
lungs. These data suggest that echocardiography 7 days after HSCT can detect early cardiac complications of
HSCT and may identify early vascular injury associated with TA-TMA.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION untreated, can cause cardiac tamponade, acutely decreasing
Hematopoietic stem cell transplantation (HSCT) is an
important and effective treatment strategy for many malig-
nancies, marrow failure syndromes, and immunodeﬁciencies
in children and young adults. The chemotherapy and radia-
tion used in HSCT may cause signiﬁcant cardiac and vascular
endothelial toxicity, resulting in complications after trans-
plant, such as pericardial effusion (PEF), left ventricular (LV)
dysfunction, and pulmonary hypertension (PH). Moreover,
heart disease is a major cause of long-term morbidity and
mortality in survivors of HSCT in childhood [1].
Predicting the impact of cardiac complications in pedi-
atric patients after HSCT is challenging because of the lack of
prospective studies evaluating these factors. PEF, if leftdgments on page 117.
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ty for Blood and Marrow Transplantation.cardiac function [2-6]. The reported incidence of PEF in
retrospective cohorts has varied from 0.2% to 19% in patients
after HSCT [7,8]. In our institution, we found a high incidence
of PEFs in patients with transplant-associated thrombotic
microangiopathy (TA-TMA) [9]. LV dysfunction has been re-
ported in patients after high-dose cyclophosphamide and
anthracyclines, and patients with LV dysfunction can initially
be asymptomatic [10-12]. PH is associated with increased
pulmonary vascular resistance and subsequent elevation in
pulmonary artery pressures [13-15]. If undiagnosed,
increased pulmonary artery pressure leads to elevated right
ventricular (RV) pressure, cardiac failure, and death
[14,16,17]. The initial symptoms of PH can be vague, and
respiratory complications after HSCT are common, making
the diagnosis of PH difﬁcult [14,18]. Jodele et al. [19] reported
a 2.3% incidence of PH with 80% mortality in a retrospective
analysis of patients transplanted at our institution. All 5 pa-
tients who developed PH had histologic evidence of TMA in
pulmonary arterioles, suggesting TA-TMA might be involved
in pathogenesis of PH after HSCT.
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determine the value of early post-transplant echocardio-
graphic screening for PH, LV dysfunction, and PEF 7 days after
HSCT in children and young adults. We hypothesized that
scheduled post-transplant echocardiographic screening at
day þ7 would identify patients at risk for cardiac complica-
tions, leading to early clinical interventions and improved
outcomes.
METHODS
In January 2012 we established uniform screening guidelines to monitor
for acute cardiac complications after HSCT in pediatric and young adult pa-
tients at Cincinnati Children’s Medical Center. All patients undergoing HSCT
had echocardiographic evaluation within 30 days before starting their HSCT
conditioning regimen (baseline echocardiography) and repeat echocardiog-
raphy on day þ7 independent of clinical condition. Patients with abnormal
echocardiography on dayþ7 had follow-up echocardiography in 7- to 14-day
intervals. Patients who were admitted to the pediatric intensive care unit
(PICU) for cardiorespiratory failure or TA-TMA or had signs or symptoms of
shock were additionally evaluated with echocardiography on arrival to the
PICU. The pediatric cardiology service evaluated patients with PEF or LV
dysfunction on echocardiography, whereas the PH service evaluated those
with elevated RV pressures or other signs of PH.
The aim of this analysis was to determine the utility of the scheduled
patient screening on day þ7 after HSCT in detecting elevated RV pressure,
PEF, and LV dysfunction and predicting adverse outcomes. Our secondary
aim was to identify risk factors associated with the development of PEF,
elevated RV pressure, and LV dysfunction.
Study Population
The study population consisted of 100 consecutive children and young
adults who received HSCT at Cincinnati Children’s Hospital Medical Center
from January 2012 to March 2013. Data were collected prospectively after
institutional review board approval. Data collected included patient de-
mographics, echocardiography data, disease and therapy characteristics,
transplant complications, and therapy outcomes. Currently accepted clinical
criteria were used for diagnosis of acute graft-versus-host disease [20],
veno-occlusive disease of the liver [21], viremias, and transplant-related
mortality [22]. Respiratory failure was diagnosed in patients requiring
endotracheal intubation and mechanical ventilation. One-year overall sur-
vival (OS) was counted from day 0 (stem cell infusion) to 1-year post-
transplant or death. Finally, we evaluated oxygen requirement, respiratory
failure, and hypertension during the ﬁrst 100 days. Patients were catego-
rized as having severe systemic hypertension if they required a continuous
antihypertensive infusion and/or 3 or more antihypertensive medications to
maintain systolic blood pressure below 95 percentile for age and height [23].
Diagnosis of TA-TMA
Patients were diagnosed with TA-TMA if the following laboratory
criteria occurred concurrently and were documented on at least 2 tests: (1)
elevated lactate dehydrogenase above the upper limit of normal, (2) new-
onset thrombocytopenia less than 50  109/L or a greater than 50%
decrease in the platelet count, (3) evidence of schistocytes in the peripheral
blood, (4) new-onset anemia below the lower limit of normal, (5) negative
Coombs test, and (6) the absence of coagulopathy. The date of TA-TMA
diagnosis was deﬁned as the ﬁrst date when all diagnostic criteria were
fulﬁlled [24-27].
Echocardiography Screening Protocol
Each HSCT patient received a comprehensive echocardiographic study at
the time points listed above. Echocardiography screening included assess-
ment of LV systolic function, PEF, and evaluation for PH. PH assessment was
performed using the PH protocol as previously described [17].
A licensed technician performed all echocardiographic studies, and
pediatric cardiologists reviewed all evaluations. A dedicated pediatric PH
specialist reviewed abnormal PH-speciﬁc echocardiograms. Pulmonary
artery pressure was estimated from a trans-tricuspid valve gradient calcu-
lated from the maximum velocity of continuous Doppler tricuspid regurgi-
tation, using a modiﬁed Bernoulli equation and assuming right central
venous pressure of 5 mm Hg [28,29]. PEF was identiﬁed from the separation
of pericardial layers detected on echocardiography [4,6]. LV function
was evaluated by assessment of the LV ejection fraction and/or shortening
fraction [11].
Elevated RV pressure was deﬁned as RV pressure greater than 35% of the
patient’s systolic blood pressure at time of echocardiography [17,28,30,31].
Intraventricular septal ﬂattening was also evaluated in the determination ofelevated RV pressure [32]. Echocardiography has a high sensitivity in pre-
dicting PH; however, the speciﬁcity is low until the estimated RV pressure
approaches 50% systemic [29-31,33]. Therefore, patients who had a docu-
mented increase in RV pressures after HSCT to 35% to 49% of systemic were
classiﬁed as “at risk for PH,” and those with RV pressures of at least 50% of
systemic were diagnosed with PH [17].
Patientswere diagnosedwithPEF if a neworenlargingPEFwas found after
transplant. PEFs were clinically classiﬁed as “small” (no interventions), “mod-
erate to large” (medical interventions required), and “tamponade” (surgical
intervention required) per standard guidelines [4]. Cardiac tamponade was
diagnosed when echocardiography demonstrated diastolic collapse of the
anterior RV free wall, right atrial collapse, left atrial, and/or LV collapse [5,34].
LV function was measured by ejection fraction, which represents the
volumetric fraction of blood pumped out of the ventricle, and fractional
shortening, an additional sensitive and speciﬁc measurement to assess LV
function. Patients found to have an ejection fraction of 50% or less and/or a
fractional shortening level less than 2 standard deviations below the age-
adjusted mean [11] were determined to have LV dysfunction. Patients
were identiﬁed as having an abnormal echocardiogram at day þ7 if they
were found to have at least 1 of the above-mentioned outcome measures:
elevated RV pressure, PEF, and/or LV dysfunction.
Statistical Analysis
Descriptive statisticswere reported asmedians, interquartile ranges, and
frequencies. Differences in categorical and continuous variables were
assessed with the Fisher exact and Wilcoxon rank sum tests, respectively.
Associated odds ratios (ORs) and their corresponding 95% conﬁdence in-
tervals (CIs)were calculatedusing theMantel-Haenszelmethod.Multivariate
analysis was performed to evaluate associations between abnormal echo-
cardiography ﬁndings at day þ7 and patient age, underlying disease, condi-
tioning regiment, graft-versus-host disease prophylaxis, and autologous
versus allogeneic HSCT. The sensitivity, speciﬁcity, and positive and negative
predictive values of elevated RV pressure and/or PEF at dayþ7 at diagnosing
TA-TMAwas estimated.
One-year OS comparing patients with abnormal echocardiography with
thosewithoutwas calculatedwithKaplan-Meier analysiswith the associated
P values calculated by log-rank analysis. Cumulative incidence of TA-TMA
with death as a competing variable was calculated by Gray’s method [35].
All patients were diagnosed with TA-TMA before 100 days post-HSCT, so
relapse was not considered as a competing risk for TA-TMA because all pa-
tients relapsed after this time.
All statistical test conducted were 2-sided, and P < .05 was considered
signiﬁcant. Cumulative incidence was calculated in R [36,37]. All other data
analyses were performed using SPSS version 20.0 (SPSS, Inc., Chicago, IL).
RESULTS
Patient Demographics
We analyzed echocardiographic screening data from 100
consecutive HSCT patients; demographics of this patient pop-
ulation are shown in Table 1. Most study patients were white,
with a median age of 5.4 years. Sixty-two percent received
transplantation for nonmalignant disorders, mainly primary
immune deﬁciencies (36%) and bone marrow failure syn-
dromes (21%). Eighty-four percent of patients underwent
allogeneic HSCT, and 86% of the allogeneic grafts were from
unrelated donors. Bone marrow was the most common stem
cell source, used in 59% of patients. Peripheral blood stem cells
were used mainly for autologous stem cell transplantation
(n ¼ 16) and patients with Fanconi anemia as an ex vivo T
celledepleted graft (n ¼ 11). Cord blood was used when a
suitable bone marrow donor was not available. The condi-
tioning regimen was myeloablative in 42% and reduced
intensity in 58% of patients; 9% of patients received total body
radiation.
OS of Patients with Abnormal Echocardiography at
Day þ7
Thirty of 100 screened patients (30%) had abnormal
echocardiography at day þ7 (Figure 1). Most patients with
abnormal echocardiography were asymptomatic, and
abnormal echocardiography was not associated with ﬂuid
retention. Thirteen patients had elevated RV pressure
Table 1
Demographics of Patients Who Underwent Echocardiographic Screening on
Day þ7
Characteristic Abnormal Day þ7
Echocardiography
(n ¼ 30)
Normal Day þ7
Echocardiography
(n ¼ 70)
P
Male 18 (60%) 47 (67%) .765
Median age at
day 0, yr (IQR)
6.8 (3.7-12.1) 5.2 (2.4-10.4) .098
Myeloablative
preparative regimen
9 (30%) 33 (47%) .127
Diagnosis .414
Malignancy 10 (33%) 28 (40%)
Immunodeﬁciency 12 (40%) 24 (34%)
Bone marrow failure 5 (17%) 16 (23%)
Genetic/metabolic 2 (7%) 2 (3%)
Benign hematology 1 (3%) 0
Stem cell source .338
Bone marrow 21 (70%) 38 (54%)
Cord 2 (7%) 8 (11%)
PBSCs 7 (23%) 24 (34%)
Donor type .198
Autologous 2 (7%) 14 (20%)
Related donor 3 (10%) 9 (13%)
Unrelated donor 25 (83%) 47 (67%)
IQR indicates interquartile range; PBSCs, peripheral blood stem cells.
Demographics with associated outcomes: elevated RV pressure, PEF, and LV
dysfunction. Statistics were performed withWilcoxon ranked sums test and
Fisher exact test.
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patients had decreased LV function. Three patients had both
elevated RV pressure and a PEF at day þ7. Patients with
abnormal echocardiography at day þ7 had a 67% OS rate at
1 year compared with 80% in patients with normal echocar-
diography (P ¼ .073). Two of the 3 patients with 2 abnormal
ﬁndings on day þ7 died before 1 year. Twenty-seven percent
of patients (8 of 30) with abnormal echocardiography at
day þ7 had an oxygen requirement at the time of echocardi-
ography, compared with 4% (3 of 70) with normal echocar-
diography at day þ7 (P ¼ .0025).Figure 1. Survival among study subjects with and without abnormal echocardiograph
was 67%  21% in subjects with abnormal echocardiography versus 80%  8% in thoseOutcomes of Abnormalities and Associated Risk Factors
Elevated RV pressure
Two of thirteen patients (15%) with elevated RV pressure at
day þ7 were diagnosed with PH by day þ30 (days 26 and 29)
(Table 2). One other patient who did not have elevated RV
pressure at day þ7 developed PH, which was diagnosed and
treatedonadmission into thePICUatdayþ39. PatientswithPH
were not catheterized for direct pressure measurement
because of concerns for morbidity. All 3 patients with PHwere
diagnosed and treated for TA-TMA before day þ100 and were
treated with PH-speciﬁc therapy, including nitric oxide,
bosentan, and/or sildenaﬁl. Two patients had a good response
to intervention, and 1 patient with PH died from cardiopul-
monary failure. Threeof 13patients at risk for PH atdayþ7had
elevated RV pressures before transplant. None of the 3 devel-
opedPHafterHSCT, and all had resolutionof their increasedRV
pressuresbydayþ100.Allpatientsdetermined tobe “at risk for
PH”were followedclinicallywith repeatechocardiographyand
close monitoring of clinical status, and no intervention was
done unless the patient was diagnosed with PH.
Our data analysis showed that patients with elevated RV
pressure at dayþ7 were signiﬁcantly more likely to have TA-
TMA (OR, 6.3; 95% CI, 1.8 to 22.3) and an oxygen requirement
in theﬁrst 100days (OR, 9.3; 95%CI, 2.3 to36.7) (Table 2).One-
year OS was decreased (61%) in 13 patients with elevated RV
pressure compared with those without (78%) (P ¼ .29).
Pericardial effusion
Seventeen patients (17%) had a PEF at day þ7. Six of 17
patients (35%) had a small PEF before transplantation. One
patientwas diagnosedwith amoderate to large PEFat dayþ7,
and 3 patients (18%) with small PEFs at day þ7 developed a
moderate to large PEF within 30 days. All 4 patients with a
moderate to large PEF receivedmedical intervention based on
screening results, and 1 required pericardiocentesis for car-
diac tamponade. TA-TMA, respiratory failure, and BK viremia
were all more common in the ﬁrst 100 days after HSCT in
patients with a PEF at day þ7 (Table 2).y at day þ7 after HSCT. The Kaplan-Meier estimate for overall survival at 1-year
without abnormal echocardiography at day þ7 (P ¼ 0.073) by the log rank test.
Table 2
Echocardiography Results and Associated Outcomes and Risk Factors
Elevated RV
Pressure
(n ¼ 13)
Normal RV
Pressure
(n ¼ 87)
P PEF
(n ¼ 17)
No PEF
(n ¼ 83)
P Decreased LV
Function
(n ¼ 3)
Normal LV
Function
(n ¼ 97)
P
aGVHD (n ¼ 33) 2 (15%) 31 (36%) .210 6 (35%) 27 (32%) 1.000 3 (100%) 30 (31%) .034
cGVHD (n ¼ 4) 1 (8%) 3 (3%) .432 0 4 (5%) 1.000 0 4 (4%) 1.000
VOD (n ¼ 1) 0 1 (1%) 1.000 0 1 (1%) 1.000 0 1 (1%) 1.000
TA-TMA (n ¼ 32) 9 (69%) 23 (26%) .004 9 (52%) 23 (28%) .051 0 32 (33%) .549
BK virus (n ¼ 36) 5 (39%) 31 (36%) 1.000 10 (59%) 26 (31%) .050 3 (100%) 33 (34%) .044
Adenovirus (n ¼ 19) 1 (8%) 18 (21%) .452 6 (35%) 13 (16%) .086 1 (33%) 18 (19%) .472
CMV (n ¼ 25) 2 (15%) 23 (26%) .508 5 (29%) 20 (24%) .759 1 (33%) 24 (25%) 1.000
EBV (n ¼ 41) 6 (46%) 35 (40%) .766 6 (35%) 35 (42%) .788 2 (67%) 39 (40%) .566
Severe hypertension (n ¼ 25) 6 (46%) 20 (23%) .094 7 (41%) 19 (23%) .136 2 (66%) 24 (25%) .165
Oxygen during ﬁrst 100 d (n ¼ 33) 10 (77%) 23 (26%) .001 9 (53%) 24 (29%) .087 1 (33%) 32 (33%) .984
Respiratory failure (n ¼ 22) 4 (31%) 18 (21%) .475 7 (41%) 15 (18%) .053 1 (33%) 21 (22%) .530
1-Year TRM (n ¼ 15) 3 (23%) 12 (14%) .407 4 (24%) 11 (13%) .279 0 15 (16%) 1.000
Death in ﬁrst year (n ¼ 24) 5 (39%) 19 (22%) .293 6 (35%) 18 (22%) .231 1 (33%) 23 (24%) .565
aGVHD indicates acute graft-versus-host disease; cGVHD, chronic graft-versus-host disease; VOD, veno-occlusive disease; CMV, cytomegalovirus; EBV, Epstein-
Barr virus; TRM, transplant-related mortality.
Outcome associations: elevated RV pressure, PEF, and LV dysfunction. Statistics were performed with Wilcoxon ranked sums test and Fisher exact test.
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Twoof 3patientswithdecreased LV function at dayþ7had
decreased function before transplantation. All 3 patientswith
decreased LV function developed aGVHD and BK viremia.
Finally, we explored severalmultivariablemodels to examine
independent risk factors for the development of abnormal
echocardiography at day þ7, but none identiﬁed signiﬁcant
associations.
TA-TMA and Day þ7 Echocardiography
Thirty-two patients (32%) were diagnosed with TA-TMA.
The cumulative incidence of TA-TMA within 100 days was
higher in patients with elevated RV pressure (P ¼ .004) and
PEF (P ¼ .051) at day þ7 than in patients without these
ﬁndings (Figure 2). All 3 patients (100%) with PEF and
elevated RV pressure, 6 of 10 patients (60%) with elevated RV
pressure alone, and 6 of 14 patients (43%) with PEF alone on
day þ7 developed TA-TMA compared with 17 of 73 patients
(23%) with no PEF or elevated RV pressure at day þ7
(P¼ .0003). Elevated RV pressure and/or PEF had a sensitivity
of 46.9% (95% CI, 29.1 to 65.3), speciﬁcity of 82.4% (95% CI,
71.2 to 90.5), positive predictive value of 55.6% (95% CI, 35.3
to 74.5), and negative predictive value of 76.7% (95% CI, 65.4Figure 2. Gray’s competing risk method was used to obtain cumulative incidence of T
two patients were diagnosed with TA-TMA. (A) 52% (9/17) of patients with PEF were
elevated RV pressure were diagnosed with TA-TMA compared to 26% (23/87) of patient
and elevated RV pressure developed TA-TMA. Sixty percent (6/10) of patients with
developed TA-TMA. Nineteen percent (14/73) of patients with no PEF or elevated RV p
stem cell transplant; PEF, Pericardial effusion; RV, right ventricular pressure; TA-TMAto 85.8). TA-TMAwas diagnosed at a median of 24 days after
HSCT (interquartile range, 15 to 36 days), and all but 2 pa-
tients developed TA-TMA after day þ7 echocardiography.
The other patients with abnormal echocardiography that
went on to develop TA-TMA were asymptomatic at day þ7.
Twelve of 15 patients (67%)with abnormal echocardiography
and TA-TMA continued to have abnormal echocardiography
30 days after HSCT.
DISCUSSION
This is the ﬁrst study to prospectively investigate the
incidence of cardiac complications in pediatric and young
adult patients shortly after undergoing HSCT. We performed
echocardiographic screening in all HSCT patients on day þ7
after transplantation independent of their clinical condition
and documented a much higher incidence of echocardio-
graphic abnormalities than previously reported by retro-
spective analyses. Thirty percent of HSCT patients had at least
1 echocardiographic abnormality at dayþ7, and 1-year post-
transplant survival was lower in these children compared
with patients without abnormalities. Thirteen percent of pa-
tients had elevated RV pressure at day þ7. Three patients
developed PH in the ﬁrst 30 days after transplant, and 2 ofA-TMA in the ﬁrst 100 days after HSCT, with death as a competing risk. Thirty-
diagnosed with TA-TMA compared to 28% (23/83). (B) 69% (9/13) patients with
s without elevated RV pressure at dayþ7. (C) All three patients (100%) with PEF
elevated RV pressure and 43% (6/14) of patients with PEF alone on day þ7
ressure at day þ7 developed TA-TMA after HSCT. HSCT indicates hematopoietic
, transplant associated thrombotic microangiopathy.
C.E. Dandoy et al. / Biol Blood Marrow Transplant 21 (2015) 113e118 117them had elevated RV pressure at day þ7 screening. We
believe that PH is underdiagnosed in the HSCT population.
Echocardiographic ﬁnding of RV pressure of 35% to 49% of
systemic has sensitivity of 83% and speciﬁcity of 72% of
diagnosing PH, likely missing less severe cases [32]. Cardiac
catheterization is the gold standard diagnostic test for PH but
is rarely used in fragile post-transplant patients and, indeed,
was not used in our cases. It is possible that early and more
aggressive use of this techniquemight improve diagnosis and
management and could be considered in severe or complex
cases [17].
Seventeen patients were diagnosed with PEF on day þ7,
and 4 patients (24%) progressed to a moderate to large PEF
within 30 days and received prompt medical or surgical
treatment. These ﬁndings suggest that day þ7 echocardiog-
raphy identiﬁes a signiﬁcant number of patients who will
develop clinically signiﬁcant PEF after HSCT where acute
clinical decompensation can be avoided by close patient
monitoring.
An interesting ﬁnding in our study was that 69% of pa-
tients with an elevated RV pressure alone and all patients
with elevated RV pressure and PEF on day 7 after HSCT were
diagnosed with TA-TMA by markers of microangiopathic
hemolysis and organ injury. The incidence of TMA we
observed is higher than that reported by others, likely
becausewe prospectivelymonitored all patients in a uniform
manner, in contrast to retrospective reports that likely
captured only the most severe cases. The incidence of TA-
TMA in this study is similar to that previously reported by
our group in a TA-TMA prospective study [38]. In the current
study the association of elevated RV pressure on dayþ7 after
HSCT and high incidence of TA-TMA in those patients may
indicate that pulmonary vascular injury occurs very early
after transplantation but is not evident by currently used TA-
TMA laboratory diagnostic criteria until later [25]. Also, many
patients with elevated RV pressure and TA-TMA received TA-
TMAespeciﬁc intervention, which may have reduced the
development of severe PH.
TA-TMA remains a very severe transplant complication in
which vascular endothelial injury affects small vessels in the
organs, resulting in thrombosis and tissue injury [22]. Early
diagnosis of TA-TMA by using current diagnostic criteria is
challenging, and elevatedRVpressuremaybe associatedwith
early presentation of TA-TMA. Further research may deter-
mine if these patients can beneﬁt from close scrutiny and
early therapy for TA-TMA. Multivisceral TA-TMA can present
with acute severePHassociatedwithveryhighmortalityafter
HSCT. Moreover, HSCT patients with pulmonary micro-
angiopathy decompensate very quickly with additional
stressors like hypoxia and often cannot be successfully
resuscitated [22]. Our group previously documented PH and
PEF in patients with prolonged symptoms of TA-TMA and
speculated that untreated TMA may affect pulmonary or
cardiac vessels, resulting in organ injury and high mortality
[19]. Our current prospective screening data suggest that PEF
and elevated RV pressure may be very early indicators of TA-
TMA and occur because of vascular injury from chemo-
therapy, radiation, or donor graft. Echocardiographymight be
a more sensitive tool to detect early vascular changes in the
lungs before the evidence of microangiopathic hemolysis in
the blood. Current TA-TMA diagnostic criteria like elevated
lactate dehydrogenase and schistocytes in peripheral blood
may be late markers of vascular injury after HSCT.
Our data suggest that cardiac and pulmonary vascular
pathology leading to signiﬁcant post-transplant complicationsis likely underestimated in HSCT population, especially in
children, andmay contribute to transplant-relatedmortality if
not treated. The association we identiﬁed between PH, PEF,
and TA-TMA should be further explored to identify markers of
vascular injury that might elucidate the mechanism of pul-
monary vascular and cardiac injury after HSCT. Such studies
are currently underway.
In summary, our data indicate that comprehensive echo-
cardiographic screening including RV pressure estimation
in allogeneic transplant recipients on day þ7 after trans-
plantationyields a high frequency of important abnormalities
[3,17,28,30]. Repeat echocardiography should be considered
in patients with abnormal dayþ7 ﬁndings and in any patient
with a new oxygen requirement, respiratory failure, or TA-
TMA. Patients with elevated RV pressure, PEF, or LV depres-
sion should undergo prompt evaluation by cardiologists and/
or PH specialists and close subsequent monitoring. Future
prospective studies are needed to validate cardiac screening
algorithms and to identify novel biomarkers that can aid in
early diagnosis of cardiac complications after HSCT, and serve
as potential therapeutic targets.
ACKNOWLEDGMENTS
The authors thank the physicians, nurses, care managers,
transplant coordinators, echocardiography technicians, and
other care providers and staff at Cincinnati Children’s Hos-
pital Medical Center and especially the patients and their
families. Dr. Dandoy performed this study as part of the
Master of Science degree in Clinical and Translational
Research, University of Cincinnati College of Medicine.
Financial disclosure: The authors have nothing to disclose.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Authorship statement: C.D., S.J., and S.M.D. designed the
study, enrolled study subjects, performed research, and wrote
the paper. C.D. and A.L. performed statistical analyses and
prepared ﬁgures. R.H., M.C., and T.D.R. reviewed echocardio-
graphic studies, provided conceptual insights for study design,
and edited themanuscript. R.S.C., Z.P., J.E., and K.C.M. provided
vital conceptual insights for study design and edited the
manuscript.
REFERENCES
1. Oefﬁnger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in
adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
2. Bodson L, Vieillard-Baron A. Cardiac tamponade. Curr Opin Crit Care.
2011;17:416-424.
3. Jung H-O. Pericardial effusion and pericardiocentesis: role of echocar-
diography. Kor Circ J. 2012;42:725-734.
4. Maisch B, Seferovic PM, Ristic AD, et al. Guidelines on the Diagnosis and
Management of Pericardial Diseases Executive Summary: The Task
Force on the Diagnosis and Management of Pericardial Diseases of the
European Society of Cardiology. Eur Heart J. 2004;25:587-610.
5. Roy CL, Minor MA, Brookhart M, Choudhry NK. Does this patient with a
pericardial effusion have cardiac tamponade? JAMA. 2007;297:
1810-1818.
6. Sagristà-Sauleda J, Soler-Soler J. Diagnosis and management of peri-
cardial effusion. World J Cardiol. 2011;3:135-143.
7. Murdych T. Serious cardiac complications during bone marrow trans-
plantation at the University of Minnesota, 1977-1997. Bone Marrow
Transplant. 2001;28:283-287.
8. Aldoss O, Gruenstein DH, Bass JL, et al. Pericardial effusion after pediatric
hematopoietic cell transplant. Pediatr Transplant. 2013;17:294-299.
9. Lerner D, Dandoy CE, Hirsch R, et al. Pericardial effusion in pediatric
SCT recipients with thrombotic microangiopathy. Bone Marrow Trans-
plant. 2014;49:862-863.
10. Fujimaki K, Maruta A, Yoshida M, et al. Severe cardiac toxicity in
hematological stem cell transplantation: predictive value of reduced left
ventricular ejection fraction. BoneMarrow Transplant. 2001;27:307-310.
11. Kantor PF, Lougheed J, Dancea A, et al. Presentation, diagnosis, and
medical management of heart failure in children: Canadian Cardio-
vascular Society guidelines. Can J Cardiol. 2013;29:1535-1552.
C.E. Dandoy et al. / Biol Blood Marrow Transplant 21 (2015) 113e11811812. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al. Cardiotoxicity associated
with high-dose cyclophosphamide therapy. Arch Intern Med. 1981;141:
758-763.
13. HumbertM, Gerry Coghlan J, KhannaD. Early detection andmanagement
of pulmonary arterial hypertension. Eur Respir Rev. 2012;21:306-312.
14. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and
treatment of pulmonary hypertension: the Task Force for the Diagnosis
and Treatment of Pulmonary Hypertension of the European Society of
Cardiology (ESC) and the European Respiratory Society (ERS), endorsed
by the International Society of Heart and Lung Transplantation (ISHLT).
Eur Heart J. 2009;30:2493-2537.
15. Roofthooft MT, Hillege HL, ten Harkel AD, et al. Pediatric pulmonary
hypertension in the Netherlands: epidemiology and characterization
during the period 1991 to 2005. Circulation. 2011;124:1755-1764.
16. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idio-
pathic, familial, and anorexigen-associated pulmonary arterial hyper-
tension in the modern management era. Circulation. 2010;122:
156-163.
17. Dandoy CE, Hirsch R, Chima R, et al. Pulmonary hypertension after
hematopoietic stem cell transplantation. Biol Blood Marrow Transplant.
2013;19:1546-1556.
18. Soubani AO, Hassoun PM. Pulmonary complications of bone marrow
transplantation. Chest. 1996;109:1066-1077.
19. Jodele S, Hirsch R, Laskin B, et al. Pulmonary arterial hypertension in
pediatric patients with hematopoietic stem cell transplanteassociated
thrombotic microangiopathy. Biol Blood Marrow Transplant. 2013;19:
202-207.
20. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-
versus-host disease in human recipients of marrow from HL-A-
matched sibling donors. Transplantation. 1974;18:295-304.
21. MyersKC, Lawrence J,MarshRA, et al. High-dosemethylprednisolone for
veno-occlusive disease of the liver in pediatric hematopoietic stem cell
transplantation recipients. Biol Blood Marrow Transplant. 2013;19:
500-503.
22. Smith AR, Majhail NS, MacMillan ML, et al. Hematopoietic cell trans-
plantation comorbidity index predicts transplantation outcomes in
pediatric patients. Blood. 2011;117:2728-2734.
23. National High Blood Pressure Education Program Working Group on
High Blood Pressure in Children. The fourth report on the diagnosis,
evaluation, and treatment of high blood pressure in children and ad-
olescents. Pediatrics. 2004;114:555-576.24. ChoBS, Yahng SA, Lee SE, et al. Validation of recently proposed consensus
criteria for thrombotic microangiopathy after allogeneic hematopoietic
stem-cell transplantation. Transplantation. 2010;90:918-926.
25. Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the
kidneys and beyond: hematopoietic stem cell transplantation-
associated thrombotic microangiopathy. Blood. 2011;118:1452-1462.
26. Ho VT, Cutler C, Carter S, et al. Blood and Marrow Transplant Clinical
Trials Network Toxicity Committee Consensus Summary: thrombotic
microangiopathy after hematopoietic stem cell transplantation. Biol
Blood Marrow Transplant. 2005;11:571-575.
27. Ruutu T, Barosi G, Benjamin RJ, et al. Diagnostic criteria for hemato-
poietic stem cell transplant-associated microangiopathy: results of a
consensus process by an International Working Group. Haematologica.
2007;92:95-100.
28. Kirkpatrick EC. Echocardiography in pediatric pulmonary hyperten-
sion. Paediatr Respir Rev. 2013;14:157-164.
29. Forﬁa PR, Vachiéry J-L. Echocardiography in pulmonary arterial
hypertension. Am J Cardiol. 2012;110:S16-S24.
30. Bossone E, D’Andrea A, D’Alto M, et al. Echocardiography in pulmonary
arterial hypertension: from diagnosis to prognosis. J Am Soc Echo-
cardiogr. 2013;26:1-14.
31. Taleb M, Khuder S, Tinkel J, Khouri SJ. The diagnostic accuracy of
Doppler echocardiography in assessment of pulmonary artery systolic
pressure: a meta-analysis. Echocardiography. 2013;30:258-265.
32. Haddad F, Guihaire J, Skhiri M, et al. Septal curvature is marker of
hemodynamic, anatomical, and electromechanical ventricular inter-
dependence in patients with pulmonary arterial hypertension. Echo-
cardiography. 2014;31:699-707.
33. Parent F, Bachir D, Inamo J, et al. A hemodynamic study of pulmonary
hypertension in sickle cell disease. N Engl J Med. 2011;365:44-53.
34. Sparano DM, Ward RP. Pericarditis and pericardial effusion: manage-
ment update. Curr Treat Options Cardiovasc Med. 2011;13:543-555.
35. Gray R. A class of K-sample tests for comparing the cumulative
incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
36. Team RDC. R: A language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2006.
37. Scrucca L, Santucci A, Aversa F. Competing risk analysis using R:
an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381-387.
38. Jodele S, Davies S, Lane A, et al. Reﬁned diagnostic and risk criteria for
HSCT-associated thrombotic microangiopathy: a prospective study in
children and young adults. Blood. 2014;124:645-653.
